Reform, regulation, and pharmaceuticals - The Kefauver-Harris amendments at 50

New England Journal of Medicine

Volumn 367, Issue 16, 2012, Pages 1481-1483

  Greene, Jeremy A ^a   Podolsky, Scott H ^b,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Center for the History of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CARDIOVASCULAR AGENT; INSULIN; NEUROLEPTIC AGENT; STEROID; SULFANILAMIDE DERIVATIVE; THALIDOMIDE; TRANQUILIZER;

CLINICAL TRIAL (TOPIC); COMPARATIVE EFFECTIVENESS; DRUG COST; DRUG EFFICACY; DRUG INDUSTRY; DRUG LEGISLATION; DRUG MARKETING; DRUG RESEARCH; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; GOVERNMENT REGULATION; HEALTH CARE MANAGEMENT; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HUMAN; LICENSING; PATENT; PATIENT CARE; PRESCRIPTION; PRIORITY JOURNAL; SHORT SURVEY; UNITED STATES;

EID: 84867606887     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp1210007     Document Type: Article

References (5)

1. Congressional Record. Washington, DC: United States Senate, 1961;107:5639.
2. Tobbell D. Pills, power, and policy: the struggle for drug reform in Cold War America and its consequences. Berkeley: University of California Press, 2012.
3. Drug Industry Antitrust Act. 87th Congress, Session 1, 1961.
4. Ethical drugs - reflections on the inquiry. N Engl J Med 1961;265:1015-6.
5. Carpenter D. Reputation and power: organizational image and pharmaceutical regulation at the FDA. Princeton, NJ: Princeton University Press, 2010.